Dietary modulation of peroxisome proliferator-activated receptor gamma

Gut

Volumn 58, Issue 4, 2009, Pages 586-593

  Marion Letellier, R ^a,c   Dechelotte P ^a   Lacucci, M ^b   Ghosh, S ^b  

^a UNIVERSITY OF ROUEN   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Faculté de Médecine Pharmacie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 15 HYDROXYICOSATETRAENOIC ACID; ALITRETINOIN; ALPHA TOCOPHEROL; AMINO ACID; ARGININE; BUTYRIC ACID; CAPSAICIN; CONJUGATED LINOLEIC ACID; CURCUMIN; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; FLAVONOID; GAMMA LINOLENIC ACID; GAMMA TOCOPHEROL; GINSENOSIDE; GLUTAMINE; HESPERIDIN; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; PROPIONIC ACID; RESVERATROL; ROSIGLITAZONE; TROGLITAZONE; UNINDEXED DRUG; VALERIC ACID;

ANTIINFLAMMATORY ACTIVITY; BACTEROIDES THETAIOTAOMICRON; CLINICAL TRIAL; COLITIS; COLON; CONCENTRATION RESPONSE; CROHN DISEASE; CROSS LINKING; CYTOKINE PRODUCTION; DIET; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ELEMENTAL DIET; ENTERIC FEEDING; ENTERITIS; FOOD; GENE EXPRESSION REGULATION; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; ISCHEMIA; LACTOBACILLUS; LACTOBACILLUS CASEI; LACTOBACILLUS CRISPATUS; LIPID DIET; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVIEW; SACCHAROMYCES BOULARDII; SEPSIS; SPICE; THERAPY EFFECT; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS;

AMINO ACIDS; BACTERIAL PHYSIOLOGICAL PHENOMENA; DIET; EICOSANOIDS; FATTY ACIDS, UNSATURATED; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; PPAR GAMMA; PROBIOTICS; SPICES;

EID: 64149109679     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.162859     Document Type: Review

References (96)

1. Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998;395:137-43.
2. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997;94:4318-23.
3. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006;55:1341-9.
4. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Mad Cham 2000;43:527-50.
5. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroantarology 2004;127:777-91.
6. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invast 1999;104:383-9.
7. Camuesco D, Galvez J, Nieto A, et al. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr 2005;135:687-94.
8. Kohno H, Suzuki R, Sugie S, et al. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancar 2005;5:46.
9. Adachi M, Kurotani R, Morimura K, et al. Peroxisome proliferator activated receptor y in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006;55:1104-13.
10. Nencioni A, Grunebach F, Zobywlaski A, et al. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 2002;169:1228-35.
11. Narayanan BA, Narayanan NK, Simi B, et al. Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancar Res 2003;63:972-9.
12. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroantarology 2003;124:1265-76.
13. Sugawara K, Olson TS, Moskaluk CA, et al.Linkageto peroxisome proliferator-activated receptor-y in SAMP1/YitFc mice and in human Crohn's disease. Gastroantarology 2005;128:351-60.
14. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-y. J Exp Mad 2005;201:1205-15.
15. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis. Am J Gastroantarol 2001;96:3323-8.
16. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroantarology 2008;134:688-95.
17. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rav 2006;58:726-11.
18. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator- activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta - Mol Call Biol Lipids 2007;1771:915-25.
19. Guan HP, Ishizuka T, Chui PC, et al. Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Ganas Dav 2005;19:453-61.
20. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5:104-12.
21. Yamazaki K, Shimizu M, Okuno M, et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells - phosphorylated RXR alpha is a critical target for colon cancer management. Gut 2007;56:1557-63.
22. Linard C, Gremy O, Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma- irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Thar 2008;324:911- 20.
23. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Cham 2000;275:4541-4.
24. Wachtershauser A, Loitsch SM, Stein J. PPAR-y is selectively upregulated in Caco-2 cells by butyrate. Biocham Biophys Ras Commun 2000;272:380-5.
25. Schwab M, Reynders V, Loitsch S, et al. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFKB signalling. Mol Immunol 2007;44:3625-32.
26. Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARγ activation. Biocham Biophys Ras Commun 2002;293:827-31.
27. Krey G, Braissant 0, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997;11:779-91.
28. Zhao G, Etherton TD, Martin KR, et al. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biocham Biophys Ras Commun 2005;336:909-17.
29. Marion-Letellier R, Butler M, Dechelotte P, et al. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor y ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells - potential for dietary modulation of peroxisome proliferator-activated receptor y in intestinal inflammation. Am J Clin Nutr 2008;87:939-48.
30. Allred CD, Talbert DR, Southard RC, et al. PPARγ1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. J Nutr 2008;138:250-6.
31. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fetty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA 2008;299:1690-7.
32. MacLean CH, Mojica WA, Newberry SJ, et al. Systemetic review of the effects of n-3 fetty acids in inflammetory bowel disease. Am J Clin Nutr 2005;82:611-9.
33. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid medietor derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Netl Acad Sci USA 2005;102:7671-6.
34. Lu J, Jilling T, Li D, et al. Polyunsetureted fetty acid supplementetion alters proinflammetory gene expression and reduces the incidence of necrotizing enterocolitis in a neonetal ret model. Padietr Ras 2007;61:427-32.
35. Lee JY, Plakidas A, Lee WH, et al. Differential moduletion of tolllike receptors by fetty acids: preferential inhibition by n-3 polyunsetureted fetty acids. J Lipid Ras 2003;44:479-86.
36. Weetherill AR, Lee JY, Zhao L, et al. Setureted and polyunsetureted fetty acids reciprocally modulete dendritic cell functions medieted through TLR4. J Immunol 2005;174:5390-7.
37. Song DH, Kang JH, Lee GS, et al. Upreguletion of tumor necrosis factor-αexpression by trans10-cis12 conjugeted linoleic acid enhances phagocytosis of RAW macrophages via a peroxisome proliferetor-activeted receptor y-dependent pethway. Cytokina 2007;37:227-35.
38. Yasui Y, Hosokawa M, Sahara T, et al. Bitter gourd seed fetty acid rich in 9c,11t,13t-conjugeted linolenic acid induces apoptosis and up-reguletes the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins Laukot Essant Fetty Acids 2005;73:113-9.
39. Ogawa J, Kishino S, Ando A, et al. Production of conjugeted fetty acids by lactic acid bacteria. J Biosci Bioang 2005;100:355-64.
40. Ewaschuk JB, Walker JW, Diaz H, et al. Bioproduction of conjugeted linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr 2006;136:1483-7.
41. Kim JM, Kim JS, Kim YJ, et al. Conjugeted linoleic acids produced by Lactobacillus dissocietes IKK-y and Hsp90 complex in Halicobactar pylori-infected gastric epithelial cells. Lab Invast 2008;88:541-52.
42. Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulete clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006;25:454-65.
43. Schopfer FJ, Lin Y, Baker PR, et al. Nitrolinoleic acid: an endogenous peroxisome proliferetor-activeted receptor gamma ligand. Proc Netl Acad Sci USA 2005;102:2340-5.
44. Bull AW, Steffensen KR, Leers J, et al. Activetion of PPARγ in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPARγ. Carcinoganasis 2003;24:1717- 22.
45. Altmann R, Hausmann M, Spottl T, et al. 13-Oxo-ODE is an endogenous ligand for PPARγ in human colonic epithelial cells. Biocham Pharmacol 2007;74:612-22.
46. Ringseis R, Piwek N, Eder K. Oxidized fet induces oxidetive stress but has no effect on NF-κB-medieted proinflammetory gene transcription in porcine intestinal epithelial cells. Inflamm Ras 2007;56:118-25.
47. Allred CD, Kilgore MW. Selective activetion of PPARγ in breast, colon, and lung cancer cell lines. Mol Call Endocrinol 2005;235:21-9.
48. Eun C, Han D, Lee S, et al. ettenuetion of colonic inflammetion by PPARγ in intestinal epithelial cells: effect on toll-like receptor pethway. Dig Dis Sci 2006;51:693-7.
49. Cuzzocrea S, Ianaro A, Wayman NS, et al. The cyclopentenone prostaglandin 15-deoxy-[Dgr]12,14- PGJ2 ettenuetes the development of colon injury caused by dinitrobenzene sulphonic acid in the ret. Br J Pharmacol 2003;138:678-88.
50. Ponferrada A, Caso JR, Alou L, et al. The role of PPARγ on restoretion of colonic homeostasis after experimental stress- induced inflammetion and dysfunction. Gastroantarology 2007;132:1791-803.
51. Lu J, Chen M, Stanley SE, et al. Effect of heterodimer partner RXRa on PPARγ activetion function-2 helix in solution. Biocham Biophys Ras Commun 2008;365:42-6.
52. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and reguletory t cell differentietion medieted by retinoic acid. Scianca 2007;317:256-60.
53. Zapeta-Gonzalez F, Rueda F, Petriz J, et al.9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activetion: inhibition of peroxisome proliferetor-activeted receptor gamma blocks some of the 9cRA activities, and precludes them to meture phenotype development. J Immunol 2007;178:6130-9.
54. Seto N, Moore FA, Kone BC, et al. Differential induction of PPAR-y by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel. Am J Physiol Gastrointast Livar Physiol 2006;290:G616-23.
55. Liu Y, Huang J, Hou Y, et al. Dietary arginine supplementetion allevietes intestinal mucosal disruption induced by Escharichia coli lipopolysaccharide in weaned pigs. Br J Nutr 2008:1-9.
56. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-medieted NF-κB activetion and proinflammetory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 1999;163:3474-83.
57. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 2007;178:4641-9.
58. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activetion. Am J Physiol Gastrointast Livar Physiol 2004;286:G367-76.
59. Deguchi Y, Andoh A, Inetomi 0, et al. Curcumin prevents the development of dextran sulfete sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007;52:2993-8.
60. Jian YT, Mai GF, Wang JD, et al. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rets colitis induced by trinitrobenzene sulfonic acid. World J Gastroantarol 2005;11:1747- 52.
61. Ukil A, Maity S, Karmakar S, et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003;139:209-18.
62. Salh B, Assi K, Templeman V, et al. Curcumin ettenuetes DNB- induced murine colitis. Am J Physiol Gastrointast Livar Physiol 2003;285:G235-43.
63. Zhang M, Deng C, Zheng J, et al. Curcumin inhibits trintrobenzene sulphonic acid-induced colitis in rats by activetion of peroxisome proliferetor-activeted receptor gamma. Int Immunopharmacol 2006;6:1233-42.
64. Siddiqui AM, Cui X, Wu R, et al. The anti-inflammetory effect of curcumin in an experimental model of sepsis is medieted by up- reguletion of peroxisome proliferetor-activeted receptor-gamma. Crit Cara Mad 2006;34:1874-82.
65. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammetory bowel disease: a pilot study. Dig Dis Sci 2005;50:2191-3.
66. Kim CS, Park WH, Park JY, et al. Capsaicin, a spicy component of hot pepper, induces apoptosis by activetion of the peroxisome proliferetor-activeted receptor gamma in HT-29 human colon cancer cells. J Mad Food 2004;7:267-73.
67. Ahn IS, Do MS, Kim SO, et al. Antiobesity effect of Kochujang (Korean fermented red pepper paste) extract in 3T3-L1 adipocytes. J Mad Food 2006;9:15-21.
68. Han KL, Jung MH, Sohn JH, et al. Ginsenoside 20(S)- protopanaxetriol (PPT) activetes peroxisome proliferetor-activeted receptor y (PPARγ) in 3T3-L1 adipocytes. Biol Pharm Bull 2006;29:110-3.
69. Hwang JT, Kim SH, Lee MS, et al. Anti-obesity effects of ginsenoside Rh2 are associeted with the activetion of AMPK signaling pethway in 3T3-L1 adipocyte. Biocham Biophys Ras Commun 2007;364:1002-8.
70. Salam NK, Huang TH, Kota BP, et al. Novel PPAR-gamma agonists identified from a netural product library: a virtual screening, induced-fit docking and biological assay study. Cham Biol Drug Das 2008;71:57-70.
71. Morikawa K, Ikeda C, Nonaka M, et al. Epigallocetechin gallete-induced apoptosis does not affect adipocyte conversion of preadipocytes. Call Biol Int 2007;31:1379-87.
72. Ulrich S, Loitsch SM, Rau 0, et al. Peroxisome proliferetor-activeted receptor y as a molecular target of resveretrol-induced moduletion of polyamine metabolism. Cancar Ras 2006;66:7348-54.
73. Campbell S, Stone W, Whaley S, et al. Gamma tocopherol upreguletes peroxisome proliferetor activeted receptor (PPAR) gamma expression in SW 480 human colon cancer cell lines. BMC Cancar 2003;3:25.
74. Vunta H, Davis F, Palempalli UD, et al. The anti-inflammetory effects of selenium are medieted through 15-deoxy-A12,14- prostaglandin J2 in macrophages. J Biol Cham 2007;282:17964-73.
75. Konturek PC, Kania J, Kukharsky V, et al. Implicetion of peroxisome proliferetor-activeted receptor y and proinflammetory cytokines in gastric carcinogenesis: link to Halicobactar pylori infection. J Pharmacol Sci 2004;96:134-43.
76. Lee SK, Kim HJ, Chi SG, et al.[Saccharomycas boulardii activetes expression of peroxisome proliferetor-activeted receptor-gamma in HT-29 cells]. Koraan J Gastroantarol 2005;45:328-34.
77. Eun CS, Han DS, Lee SH, et al. [Probiotics may reduce inflammetion by enhancing peroxisome proliferetor activeted receptor gamma activetion in HT-29 Cells.]. Koraan J Gastroantarol 2007;49:139- 16.
78. Ewaschuk J, Endersby R, Thiel D, et a/. Probiotic bacteria prevent hepetic damage and maintain colonic barrier function in a mouse model of sepsis. Hepeto/ogy 2007;46:841-50.
79. 2 acts as a signal transducing molecule activeting peroxisome proliferetor activeted receptor-y in the intestinal mucosa. Gastroenterology 2008;135:1216-27.
80. Wild GE, Drozdowski L, Tartaglia C, et a/. Nutritional moduletion of the inflammetory response in inflammetory bowel disease-from the molecular to the integretive to the clinical. World J Gastroenterol 2007;13:1-7.
81. Julio Galvez MER-CAZ. Effects of dietary fiber on inflammetory bowel disease. Mol Nutr Food Res 2005;49:601-8.
82. Gassull MA. Review article: the intestinal lumen as a therapeutic target in inflammetory bowel disease. Aliment Pharmacol Ther 2006;24(suppl 3):90-5.
83. Aldhous MC, Meister D, Ghosh S. Modificetion of enteral diets in inflammetory bowel disease. Proc Nutr Soc 2001;60:457-61.
84. Ferguson A, Glen M, Ghosh S. 5 Crohn's disease: nutrition and nutritional therapy. Bailliére's Clin Gastroenterol 1998;12:93-114.
85. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fet composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut 2002;51:164-8.
86. Bamba T, Shimoyama T, Sasaki M, et al. Dietary fet ettenuetes the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepetol 2003;15:151-7.
87. Caughey GE, Mantzioris E, Gibson RA, et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fetty acids from vegetable oil or fish oil. Am J Clin Nutr 1996;63:116-22.
88. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric- coeted fish-oil preparetion on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
89. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fetty acids and low carbohydrete diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 1996;31 :778-85.
90. De Ley M, de Vos R, Hommes DW, et al. Fish oil for induction of remission in ulceretive colitis. Cochrane Detabase Syst Rev 2007:CD005986.
91. Hart AR, Luben R, Olsen A, et al. Diet in the aetiology of ulceretive colitis: a European prospective cohort study. Digestion 2008;77:57-64.
92. Di Sabetino A, Morera R, Ciccocioppo R, et al. Oral butyrete for mildly to moderetely active Crohn's disease. Aliment Pharmacol Therap 2005;22:789-94.
93. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulceretive colitis: randomized, multicenter, double- blind, placebo-controlled trial. Clin Gastroenterol Hepetol 2006;4:1502- 6.
94. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treetment of Crohn's disease. Dig Dis Sci 2000;45:1462-1.
95. Pronio A, Montesani C, Butteroni C, et al. Probiotic administretion in petients with ileal pouch-anal anastomosis for ulceretive colitis is associeted with expansion of mucosal reguletory cells. Inflamm Bowel Dis 2008;14:662-8.
96. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treetment of active pouchitis. Dis Co on Rectum 2007;50:2075-84.